Stimulant Selection and Management for ADHD

Initial Stimulant Selection

The American Academy of Child and Adolescent Psychiatry recommends starting with methylphenidate as first-line therapy, and if there is inadequate response after adequate dosing and duration, switch to an amphetamine preparation as the next option, as approximately 70% respond to either stimulant alone but nearly 90% respond when both classes are tried sequentially 1, 2, 3, 4, 5
Both methylphenidate and amphetamines are equally effective first-line stimulants with large effect sizes for ADHD symptom reduction, but methylphenidate should be initiated first in most patients 1, 2, 5
For preschool-aged children, methylphenidate is specifically recommended as first-line despite amphetamine having FDA approval under age 6, due to stronger evidence in this age group 5
Extended-release formulations should be strongly preferred over immediate-release for both medication classes due to better adherence, lower rebound effects, more consistent symptom control, and reduced diversion potential 1, 2, 5, 6

Start with 5 mg twice daily for children, or 5 mg once daily for adults, and increase weekly by 5-10 mg increments based on symptom control and tolerability 3
Maximum daily doses: 60 mg for adults, with some patients requiring up to 1.0 mg/kg or 65 mg total daily dose when higher doses are clearly documented as necessary without side effects 3, 6
For amphetamine/dextroamphetamine titration, start with 2.5 mg once or twice daily for children, or 2.5-5 mg for adults, and increase weekly by 2.5-5 mg increments based on response 3

Anxiety is NOT a contraindication to stimulant use for either medication class, though careful monitoring is required 5, 6
For comorbid sleep disturbances, consider timing of doses and potentially alpha-2 agonists as adjunctive or alternative therapy 2, 6
For comorbid substance use disorder, screen thoroughly before prescribing any stimulant, and consider formulations with lower abuse potential or non-stimulant alternatives 5, 6

Blood pressure and pulse at baseline and regularly during treatment, as both stimulants cause statistically significant but usually small increases 7, 5
Height and weight monitoring, as both stimulants cause dose-related reductions in growth velocity 7, 5
Assessment for common adverse effects: decreased appetite, sleep disturbances, headaches, irritability, stomach pain 5
Screen for signs of misuse, diversion, or tolerance, particularly in adolescents and adults 5